Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of Sepsis Scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive Chemotherapy
NCT05249894 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2022-03-28
Summary
Evaluation of Infective Risk, Efficacy of Bacterial Prophylaxis and Validation of sepsis scores NEWS (National Early Warning Score) and qSOFA (Quick Sequential Organ Failure Assessment) in Patient With Acute Myeloid Leukemia Treated With Intensive Chemotherapy
Conditions
Sponsors & Collaborators
-
A.O.U. Città della Salute e della Scienza
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-23
- Primary Completion
- 2022-09-01
- Completion
- 2022-09-01
Countries
- Italy
Study Locations
More Related Trials
-
Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
NCT07074496 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia
NCT00510939 ·Status: UNKNOWN ·Phase: PHASE2
-
Role of Cbc Indices in Acute Lymphoblastic Leukemia Patients
NCT06746571 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients
NCT03594149 ·Status: COMPLETED ·Phase: PHASE3
-
Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative
NCT05750706 ·Status: COMPLETED
-
An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
NCT02472145 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia
NCT00251368 ·Status: COMPLETED ·Phase: PHASE1
-
S9031-S9126-S9333-S9500-B Biomarker Expression in Patients With Acute Myeloid Leukemia
NCT01059734 ·Status: COMPLETED
-
A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
NCT02859948 ·Status: UNKNOWN ·Phase: PHASE1
-
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
NCT03298984 ·Status: COMPLETED ·Phase: PHASE1
-
Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia
NCT03075969 ·Status: UNKNOWN
-
Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase
NCT00027144 ·Status: COMPLETED ·Phase: PHASE1
-
The Role of Ruxolitinib in Secondary Acute Myelogenous Leukemia Evolving From Myeloproliferative Neoplasm
NCT03558607 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia
NCT07101497 ·Status: RECRUITING ·Phase: PHASE2
-
A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia
NCT02848248 ·Status: TERMINATED ·Phase: PHASE1
-
NLA101 in Adults Receiving High Dose Chemotherapy for AML
NCT03301597 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia
NCT02042911 ·Status: COMPLETED ·Phase: PHASE2
-
Prospective Collection of Biological Data of Prognostic Relevance in Patients With B-Cell Chronic Lymphocytic Leukemia
NCT00917540 ·Status: UNKNOWN
-
A Study of BN104 in the Treatment of Acute Leukemia
NCT06052813 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients
NCT00957385 ·Status: COMPLETED ·Phase: PHASE2
-
Autoimmune Cytopenia and BcR Inhibitors
NCT03469895 ·Status: UNKNOWN
-
A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment
NCT04241549 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00963105 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction
NCT01578954 ·Status: COMPLETED ·Phase: PHASE1
-
A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia
NCT05672355 ·Status: SUSPENDED ·Phase: PHASE2